BerGenBio

Regulatory Filings • Aug 20, 2024

BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer

BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer

Bergen, Norway, August 20, 2024, - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical needs, announced today a collaboration with Tempus, a

technology company leading the adoption of AI to advance precision medicine and

patient care, to advance the clinical development of BerGenBio's selective AXL

inhibitor bemcentinib in first line (1L) Non-Small Cell Lung Cancer (NSCLC)

patients with STK11 mutations (STK11m). BerGenBio's on-going BGBC016 Phase 1b/2a

trial is designed to assess the benefit of adding bemcentinib to the current

standard of care treatment (immunotherapy + doublet chemotherapy) in 1L STK11m

patients, a population with poor outcomes and no specific therapies today.

The collaboration will provide BerGenBio with access to a tailored cohort of

Tempus' real-world clinical and molecular data that is intended to establish a

synthetic control to provide a contextual benchmark for BerGenBio's innovative

study, which aims to address the urgent medical need for effective treatments in

STK11m NSCLC patients. Tempus' comprehensive, AI-enabled platform will enable

BerGenBio to receive customized analyses of Tempus data and gain deeper insights

into the genomic landscape and therapeutic responses of NSCLC patients with

STK11m.

Upon conclusion of the BGBC016 study, the parties intend to present insights

derived from the resulting data to appropriate regulatory agencies as a next

step in the further development of bemcentinib.

Martin Olin, CEO of BerGenBio, expressed enthusiasm about the collaboration,

stating, "We are excited to partner with Tempus to harness the power of their

advanced technology in our mission to improve outcomes for NSCLC patients with

STK11 mutations. By integrating Tempus' platform into our study, we aim to

enhance our understanding of the disease biology and treatment outcomes,

ultimately driving our ability to accelerate further development of

bemcentinib".

"We are excited to collaborate with BerGenBio to accelerate the development of

precision therapies for STK11m NSCLC patients," said Kate Sasser, Chief

Scientific Officer at Tempus. Together, we aim to unlock new insights that will

ultimately improve patient outcomes and redefine the standard of care in this

challenging disease setting."

For further information, please contact:

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Investor Relations / Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visit www.bergenbio.com

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.